CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
A232301CD Alliance AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients Cancer Prevention and Control CIRB
AALL0331 COG Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL): A Phase III Group-Wide Study Pediatric CIRB
AALL03B1 COG Classification of Acute Lymphoblastic Leukemia Pediatric CIRB
AALL03N1 COG Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia Pediatric CIRB
AALL0433 COG Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies. A Groupwide Phase III Study Pediatric CIRB
AALL0434 COG Intensified Methotrexate; Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma: A Groupwide Phase III Study Pediatric CIRB
AALL05B1 COG A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens Pediatric CIRB
AALL0622 COG Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969; NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL): A Groupwide Phase II/III Study Pediatric CIRB
AALL0631 COG A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy FLT3 Inhibition (CEP-701; Lestaurtinib; IND#76431; NSC#617807) Pediatric CIRB
AALL06N1 COG A Study of Neurocognitive Function in Children Treated for ALL: A Group-wide; Non-Therapeutic Companion Study to AALL0232 Pediatric CIRB